Search

Your search keyword '"Tougeron, D."' showing total 428 results

Search Constraints

Start Over You searched for: Author "Tougeron, D." Remove constraint Author: "Tougeron, D."
428 results on '"Tougeron, D."'

Search Results

1. Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAFV600-mutated melanoma

2. Esophageal cancer - French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, RENAPE, SNFCP, AFEF, SFR)

3. Efficacy of immunotherapy in mismatch repair-deficient advanced colorectal cancer in routine clinical practice. An AGEO study

4. Prediction of response to immune checkpoint blockade in patients with metastatic colorectal cancer with microsatellite instability

8. 608P Resectability of colorectal liver metastases (CLM) with aflibercept plus FOLFIRI: Results from a prospective French cohort

10. Circulating tumor DNA at baseline for individualized prognostication in patients with chemotherapy-naïve metastatic colorectal cancer. An AGEO prospective study

11. Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials

12. RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study

13. OC-0277 Capecitabine or 5-fluorouracil infusion with radiotherapy of anal cancers in the FFCD-Anabase cohort

14. Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort

18. EE416 Cost-Effectiveness of Pembrolizumab Monotherapy for First-Line Treatment in Adult Patients with Microsatellite Instability High/Mismatch Repair-Deficient Metastatic Colorectal Cancer From a French Perspective

19. Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001–02)

20. 68O Impact of mutation status on efficacy outcomes in TOPAZ-1: A phase III study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+GC) in advanced biliary tract cancer (BTC)

21. 86P Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study

22. LBA23 Avelumab versus standard second-line treatment chemotherapy in metastatic colorectal cancer (mCRC) patients with microsatellite instability (MSI): The SAMCO-PRODIGE 54 randomised phase II trial

23. 365P Prognostic value of Lynch syndrome, BRAFV600E and RAS mutation status in dMMR/MSI-H metastatic colorectal cancer in a pooled analysis of the national Dutch and French cohorts

24. 449TiP Evaluation of regorafenib treatment PERSOnalization based on therapeutic drug monitoring in patients with metastatic colorectal cancer (mCRC): RePERSO study

25. 429P Management of localized anal cancer and prognostic factors in the elderly: Results of the French multicenter cohort FFCD – ANABASE

26. O-1 Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase 3 TOPAZ-1 study

28. OC-0270 Final results of the French national cohort ANABASE : treatment and outcome in anal cancer

29. MO-0226 Clinical outcomes of HIV-positive patients with anal cancer in the ANABASE multicentric cohort

30. Deep Treatment Response Assessment and Prediction of Colorectal Cancer Liver Metastases

33. Efficacité et toxicité de la (chimio)radiothérapie chez les patients séropositifs pour le VIH atteints d’un carcinome épidermoïde du canal anal, analyse en sous-groupe de la cohorte multicentrique Anabase

35. 508TiP PRODIGE 68 - UCGI 38 - SOREGATT: A randomized phase II study comparing the sequences of regorafenib (reg) and trifluridine/tipiracil (t/t) after failure of standard therapies in patients (pts) with metastatic colorectal cancer (mCRC)

37. 1472P Circulating tumor DNA in unresectable pancreatic cancer is a strong predictor of response to first-line therapy: The KRASCIPANC study

38. 462P Heterogeneity of mismatch repair status between primary tumors and matched metastases in metastatic colorectal cancer

39. 66P Targeted treatment (TT) after immune checkpoint inhibitors (ICIs) in BRAF V600E mutated (BRAFm) and deficient mismatch repair or microsatellite instability high (dMMR/MSI-H) metastatic colorectal cancer (mCRC).

44. 1020MO AdvanTIG-203: Phase II randomized, multicenter study of ociperlimab (OCI) + tislelizumab (TIS) in patients (pts) with unresectable, locally advanced, recurrent/metastatic esophageal squamous cell carcinoma (ESCC) and programmed cell death-ligand 1 (PD-L1) positivity

47. 1555P Cell-free DNA analysis in patients with metastatic gastroesophageal adenocarcinoma: Preliminary results of the REGIRI - PRODIGE 58 ancillary study

49. 121P PemiBil: Efficacy and safety of pemigatinib in advanced cholangiocarcinoma with FGFR2 fusions/rearrangements in real-world, results of multicentric French cohort from ACABI consortium

Catalog

Books, media, physical & digital resources